OC
AZN icon

Oarsman Capital’s AstraZeneca AZN Stock Holding History

Oarsman Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Sell
16,428
-125
-0.8% -$23.5K 0.33% 50
2026
Q1 		$3.26M Buy
16,553
+2,231
+16% +$430K 0.41% 41
2025
Q4 		$2.63M Buy
14,322
+1,591
+12% +$279K 0.34% 52
2025
Q3 		$1.95M Buy
12,731
+1,066
+9% +$161K 0.27% 64
2025
Q2 		$1.63M Sell
11,665
-188
-2% -$26.3K 0.26% 77
2025
Q1 		$1.74M Buy
11,853
+1,863
+19% +$270K 0.31% 68
2024
Q4 		$1.31M Sell
9,990
-575
-5% -$80.5K 0.23% 83
2024
Q3 		$1.65M Buy
10,565
+1,571
+17% +$254K 0.3% 70
2024
Q2 		$1.4M Buy
8,994
+1,972
+28% +$297K 0.31% 71
2024
Q1 		$951K Sell
7,022
-716
-9% -$94.8K 0.23% 92
2023
Q4 		$1.04M Buy
7,738
+187
+2% +$24.3K 0.28% 85
2023
Q3 		$1.02M Buy
7,551
+27
+0.4% +$3.69K 0.43% 64
2023
Q2 		$1.08M Sell
7,524
-39
-0.5% -$5.74K 0.47% 58
2023
Q1 		$1.05M Buy
7,563
+673
+10% +$90.5K 0.49% 55
2022
Q4 		$934K Sell
6,890
-1,680
-20% -$211K 0.48% 61
2022
Q3 		$940K Sell
8,570
-125
-1% -$15.9K 0.5% 57
2022
Q2 		$1.15M Sell
8,695
-190
-2% -$24.9K 0.57% 53
2022
Q1 		$1.18M Buy
8,885
+312
+4% +$37.4K 0.46% 65
2021
Q4 		$999K Buy
8,573
+73
+0.9% +$8.59K 0.39% 79
2021
Q3 		$1.02M Sell
8,500
-8
-0.1% -$931 0.41% 78
2021
Q2 		$1.02M Buy
+8,508
New +$933K 0.4% 80

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Oarsman Capital's AZN Position: Q2 2026 in Review

Oarsman Capital reduced its AstraZeneca (AZN) stake by 0.76% in Q2 2026, selling an estimated $23.5K and leaving 16,428 shares worth $3.12M. The position accounts for 0.33% of the portfolio, ranked #50.

Oarsman Capital first reported a position in AZN in Q2 2021 and has held it in 21 quarters since. The position peaked at $3.26M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Oarsman Capital held 16,428 shares of AstraZeneca worth $3.12M as of Q2 2026.
  • Oarsman Capital sold 125 AstraZeneca shares in Q2 2026, an estimated $23.5K.
  • AstraZeneca made up 0.33% of Oarsman Capital's portfolio in Q2 2026, its #50 holding.
  • Oarsman Capital first reported a position in AstraZeneca in Q2 2021 and has held it in 21 quarters since.
  • Oarsman Capital's AstraZeneca position peaked at $3.26M in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Oarsman Capital's 13F filing for Q2 2026, filed 7 Aug 2026.